When the drug maker Biogen pitched its Alzheimer’s treatment to a panel of independent experts last November, most saw muddled, confusing data that raised doubts about whether it would benefit patients. Billy Dunn saw a “home run.”
Dunn, the Food and Drug Administration’s chief of neuroscience, told the experts that the data supporting Aduhelm were “extremely persuasive,” and, in a departure from the neutral tone that regulators typically strike, he called on the agency to “exercise the broadest flexibility” to approve the treatment. Seven months later, it did.
Create a display name to comment
This name will appear with your comment
